Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Long-acting risperidone reduces costs in schizophrenia

    • 9 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Long-acting risperidone reduces costs in schizophrenia. Pharmacoecon. Outcomes News 443, 6 (2003). https://doi.org/10.1007/BF03277195

    Download citation


    • Schizophrenia
    • Risperidone
    • Outcome News
    • Schizophrenia Patient
    • Schizoaffective Disorder